This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: Celgene, MorphoSys Strike Deal on Blood Cancer Drug

NEW YORK ( The Deal) - Celgene Corp. (CELG - Get Report) has made a move to solidify its future in the multiple myeloma space, inking a licensing deal with Germany's MorphoSys AG for its MOR202 drug that could be worth $818 million to MorphoSys.

Munich-based MorphoSys gets an up-front license fee of 70.8 million Euros ($92 million) and Celgene will purchase $60 million worth of new shares of the company, the parties said Thursday.

Multiple myeloma is a blood cell cancer affecting white blood cells that produce antibodies. It's fairly rare, accounting for only about 1% of cancers, but until recently death occurred between one and four years after diagnosis. With newer drugs, such as those developed by Celgene, survival in many with the disease has been extended several years. Celgene, based in Summit, N.J., is a leader in MM treatments with its U.S.-approved brands Thalomid, Revlimid and Pomalyst. MOR202 would offer an option for revenue replacement in that space as those brands lose exclusivity.

The transaction must be cleared by U.S. antitrust authorities under the Hart-Scott-Rodino Act. The price of shares will be determined following that clearance. It will include a premium of at least 15% of the closing price of the shares prior to the parties signing the agreement.

Total value of the transaction could hit $818 million for MorphoSys, which may be entitled to additional development, regulatory and sales milestones plus tiered double-digit royalties on net sales outside a co-promotion territory.

Celgene secures worldwide rights to MOR202 while sharing the rights with MorphoSys to co-promote the drug candidate in Europe if it is approved there. MorphoSys retains 50-50 profit sharing in its co-promotion territory.

MOR202 is a fully human monoclonal antibody targeting CD38 and is in development to treat MM and leukemias. It is now in a Phase 1/2a trial in patients with relapsed/refractory MM. MorphoSys and Celgene will share in the costs of development of the mAb for MM and other indications, with MorphoSys paying one-third of the costs and Celgene two-thirds.

Patients continue to need new options for treatment of the disease, said Mark Alles, executive vice president and global head of hematology and oncology at Celgene. "Strategic investments in next-generation medical innovation make it possible for physicians to turn incurable cancers like MM into chronic, more manageable diseases."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CELG $115.69 -2.50%
JNJ $100.74 -0.34%
SNY $52.88 2.20%
AAPL $132.80 1.90%
FB $82.29 0.93%

Markets

DOW 18,081.11 +0.97 0.01%
S&P 500 2,116.36 -1.33 -0.06%
NASDAQ 5,078.1770 -13.9080 -0.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs